Status:
COMPLETED
131-I-TM-601 Study in Adults With Solid Tumors
Lead Sponsor:
TransMolecular
Conditions:
Breast Cancer
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic imaging) in patients with re...
Detailed Description
This is a multi-center, open label, non-randomized, sequential, within-patient dose-escalation study in patients with recurrent or refractory primary solid tumors with metastatic involvement (includin...
Eligibility Criteria
Inclusion
- Histologically confirmed recurrent or refractory primary solid tumor malignancy. Primary tumor cell type is one of the following: breast, non-small cell lung, melanoma, colorectal, prostatic adenocarcinoma (hormone refractory) or glioma. Note: Patients with a primary solid tumor cell type not listed above, meeting all other selection criteria may be considered eligible, on a case by case basis
- Demonstration of distant metastatic involvement as seen with standard clinical non-invasive imaging techniques (CT/MRI) or on biopsy. Note: on a case-by-case basis, patients with a locally recurrent, unresectable (inoperable) tumor may be considered for inclusion
- Refractory to standard curative treatment
- At least 18 years of age
- Baseline Karnofsky Performance Status (KPS) of 60-100%
- Life expectancy, based on investigator judgement, of greater than 3 months
- Adequate organ and marrow function (as defined in protocol)
- Women of child-bearing potential must have a negative pregnancy test, refrain from nursing, and must agree to use appropriate contraception for the duration of the trial
Exclusion
- Prior cytotoxic chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients who have not sufficiently recovered from adverse events due to previously administered agents
- Concurrent treatment with investigational or commercial agents or therapies administered with the intent to treat the patient's malignancy, including chemotherapy, immunotherapy, biological response modifiers, or palliative radiotherapy. Possible exceptions (at the discretion of the investigator) are for hormonal therapy for breast and prostate cancer, hematologic, analgesic, biphosphonate, and any other form of supportive therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to 131-I-labeled chlorotoxin (e.g. iodine or iodine-containing drugs)
- Patients with uncontrolled intercurrent illness.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00379132
Start Date
August 1 2006
End Date
August 1 2008
Last Update
March 31 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Northwestern University, The Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States, 60611
3
University of Chicago
Chicago, Illinois, United States, 60637
4
Tufts - New England Medical Center
Boston, Massachusetts, United States, 02111